((自动化翻译由路透提供，请见免责声明 ))
12月23日 - ** 美国制药商礼来 股价盘前上涨2.5%，报787美元
** 美国食品和药物管理局周五批准 (link) 礼来公司的减肥药 Zepbound 用于治疗中度至重度睡眠呼吸暂停，使其成为美国食品和药物管理局批准的首个治疗这种常见睡眠障碍的药物。
** 阻塞性睡眠呼吸暂停是一种患者在睡眠时短暂停止呼吸的病症
** 睡眠呼吸暂停设备制造商瑞思迈 和Inspire Medical 的股价在盘前交易中分别下跌约3%和4
** 一些分析师此前曾表示 (link)，他们预计Zepbound获批后，患者对睡眠呼吸暂停器械的需求会受到干扰，但制造商们已经回避了这种担忧。
** 截至上次收盘，LLY 今年上涨了约 32%，RMD 今年上涨了约 38%，而 INSP 今年下跌了约 8
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.